SR One reinvested in a series B round for the degenerative disorder drug developer that was led by venture fund Logos Capital.
Design Therapeutics, a US-based developer of therapeutics for degenerative disorders spun out of University of Wisconsin-Madison, has closed a $125m series B round featuring SR One, the venture capital firm funded by pharmaceutical firm GlaxoSmithKline.
Biotech-focused VC fund Logos Capital led the round, which included returning investors Cormorant Asset Management, Quan Capital and WestRiver Group.
RA Capital Management, Janus Henderson Investors, Surveyor Capital, Wellington Management, Avoro Capital Advisors and Vivo Capital also invested, with funds and accounts managed…
